Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance

被引:30
|
作者
Metcalfe, John Z. [1 ]
Streicher, Elizabeth [2 ,3 ]
Theron, Grant [2 ,3 ]
Colman, Rebecca E. [4 ]
Allender, Christopher [5 ]
Lemmer, Darrin [5 ]
Warren, Rob [2 ,3 ]
Engelthaler, David M. [5 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, 1001 Potrero Ave,Rm 5K1, San Francisco, CA 94110 USA
[2] Stellenbosch Univ, Fac Med & Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Tygerberg, South Africa
[3] Stellenbosch Univ, Fac Med & Hlth Sci, SAMRC Ctr TB Res, Div Mol Biol & Human Genet, Tygerberg, South Africa
[4] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA
[5] Translat Genom Res Inst, Flagstaff, AZ USA
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
next-generation sequencing; Sanger sequencing; drug-resistant tuberculosis; diagnostics; DRUG-RESISTANCE; FLUOROQUINOLONE RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; HETERO-RESISTANCE; GENOMIC ANALYSIS; SOUTH-AFRICA; HETERORESISTANCE; SUSCEPTIBILITY; MUTATIONS; DIAGNOSIS;
D O I
10.1164/rccm.201703-0556OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Minority drug-resistant Mycobacterium tuberculosis subpopulations can be associated with phenotypic resistance but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays. Objectives: To determine the role of targeted next-generation sequencing in resolving these minor variant subpopulations. Methods: We used single molecule overlapping reads (SMOR), a targeted next-generation sequencing approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance-determining regions (study group). Isolates also underwent single-colony selection on antibiotic-containing agar, blinded to sequencing results. As a positive control, isolates with multiple colocalizing chromatogram peaks were also analyzed (control group). Measurements and Main Results: Among 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49%) and 45 (33%) of 135 total heteroresistant RAVs at frequencies less than 5% and less than 1% of the total mycobacterial population, respectively. In the study group, SMOR detected minor resistant variant subpopulations in 80% (n = 20/25) of isolates with no Sanger-identified RAVs (median subpopulation size, 1.0%; interquartile range, 0.2-3.9%). Single-colony selection on drug-containing media corroborated SMOR results for 90% (n = 18/20) of RAV-containing specimens, and the absence of RAVs in 60% (n = 3/5) of isolates. Overall, Sanger sequencing was concordant with SMOR for 77% (n = 53/69) of macroheteroresistant (5-95% total population), but only 5% of microheteroresistant (< 5%) subpopulations (n = 3/66) across both groups. Conclusions: Cryptic minor variant mycobacterial subpopulations exist below the resolving capability of current drug susceptibility testing methodologies, and may explain an important proportion of false-negative resistance determinations.
引用
收藏
页码:1191 / 1201
页数:11
相关论文
共 50 条
  • [21] Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
    de Vos, Margaretha
    Ley, Serej D.
    Cox, Helen
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2178 - 2180
  • [22] Phenotypic modulation in Mycobacterium tuberculosis infected neutrophil during tuberculosis
    Pokkali, Supriya
    Rajavelu, Priya
    Sudhakar, R.
    Das, Sulochana D.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2009, 130 (02) : 185 - 192
  • [23] Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis
    Morlock, GP
    Crawford, JT
    Butler, WR
    Brim, SE
    Sikes, D
    Mazurek, GH
    Woodley, CL
    Cooksey, RC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2291 - 2295
  • [24] Recasting resistance to Mycobacterium tuberculosis
    Andrews, Jason R.
    NATURE IMMUNOLOGY, 2024, 25 (08) : 1316 - 1318
  • [25] Drug resistance in Mycobacterium tuberculosis
    Johnson, Rabia
    Streicher, Elizabeth M.
    Louw, Gail E.
    Warren, Robin M.
    van Helden, Paul D.
    Victor, Thomas C.
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2006, 8 : 97 - 111
  • [26] Multidrug resistance in Mycobacterium tuberculosis
    Heym, B
    Cole, ST
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1997, 8 (01) : 61 - 70
  • [27] Resistance of Mycobacterium tuberculosis to daptomycin
    Moon, Cheol
    Jang, Ji-Chan
    INFECTIOUS DISEASES, 2016, 48 (07) : 569 - 570
  • [28] Acid Resistance in Mycobacterium tuberculosis
    Vandal, Omar H.
    Nathan, Carl F.
    Ehrt, Sabine
    JOURNAL OF BACTERIOLOGY, 2009, 191 (15) : 4714 - 4721
  • [29] DRUG RESISTANCE OF MYCOBACTERIUM TUBERCULOSIS
    Alorainy, Mohammad S.
    BULLETIN OF PHARMACEUTICAL SCIENCES, 2010, 33 : 235 - 240
  • [30] Mycobacterium tuberculosis with extensive resistance
    Labie, Dominique
    M S-MEDECINE SCIENCES, 2007, 23 (02): : 205 - 209